![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: WNT4 |
Gene summary for WNT4 |
![]() |
Gene information | Species | Human | Gene symbol | WNT4 | Gene ID | 54361 |
Gene name | Wnt family member 4 | |
Gene Alias | SERKAL | |
Cytomap | 1p36.12 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P56705 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54361 | WNT4 | C30 | Human | Oral cavity | OSCC | 1.34e-08 | 7.41e-01 | 0.3055 |
54361 | WNT4 | C43 | Human | Oral cavity | OSCC | 4.94e-08 | 2.25e-01 | 0.1704 |
54361 | WNT4 | C51 | Human | Oral cavity | OSCC | 1.33e-11 | 8.69e-01 | 0.2674 |
54361 | WNT4 | SYSMH2 | Human | Oral cavity | OSCC | 4.95e-10 | 4.70e-01 | 0.2326 |
54361 | WNT4 | SYSMH3 | Human | Oral cavity | OSCC | 2.39e-37 | 1.34e+00 | 0.2442 |
54361 | WNT4 | SYSMH4 | Human | Oral cavity | OSCC | 2.58e-05 | 6.66e-02 | 0.1226 |
54361 | WNT4 | SYSMH5 | Human | Oral cavity | OSCC | 1.52e-07 | 5.73e-01 | 0.0647 |
54361 | WNT4 | P1_S1_AK | Human | Skin | AK | 1.01e-08 | 2.43e-01 | -0.3399 |
54361 | WNT4 | P2_S3_AK | Human | Skin | AK | 8.09e-18 | 4.11e-01 | -0.3287 |
54361 | WNT4 | P2_S4_SCCIS | Human | Skin | SCCIS | 6.41e-11 | 4.24e-01 | -0.3043 |
54361 | WNT4 | P3_S6_AK | Human | Skin | AK | 1.84e-05 | 3.03e-01 | -0.3256 |
54361 | WNT4 | P4_S8_cSCC | Human | Skin | cSCC | 1.30e-23 | 6.44e-01 | -0.3095 |
54361 | WNT4 | P5_S10_cSCC | Human | Skin | cSCC | 1.00e-21 | 3.76e-01 | -0.299 |
54361 | WNT4 | P1_cSCC | Human | Skin | cSCC | 1.23e-09 | 6.43e-01 | 0.0292 |
54361 | WNT4 | P2_cSCC | Human | Skin | cSCC | 4.55e-06 | 3.35e-01 | -0.024 |
54361 | WNT4 | P4_cSCC | Human | Skin | cSCC | 1.29e-30 | 6.09e-01 | -0.00290000000000005 |
54361 | WNT4 | P10_cSCC | Human | Skin | cSCC | 3.86e-09 | 4.67e-01 | 0.1017 |
54361 | WNT4 | cSCC_p10 | Human | Skin | cSCC | 2.35e-13 | 3.76e-01 | -0.2095 |
54361 | WNT4 | cSCC_p11 | Human | Skin | cSCC | 5.59e-18 | 3.62e-01 | -0.2102 |
54361 | WNT4 | cSCC_p4 | Human | Skin | cSCC | 3.92e-06 | 1.66e-01 | -0.2022 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00018377 | Oral cavity | OSCC | epithelial to mesenchymal transition | 82/7305 | 157/18723 | 5.09e-04 | 2.98e-03 | 82 |
GO:00075657 | Oral cavity | OSCC | female pregnancy | 98/7305 | 193/18723 | 5.66e-04 | 3.27e-03 | 98 |
GO:00066945 | Oral cavity | OSCC | steroid biosynthetic process | 89/7305 | 173/18723 | 5.77e-04 | 3.30e-03 | 89 |
GO:00302175 | Oral cavity | OSCC | T cell differentiation | 126/7305 | 257/18723 | 6.51e-04 | 3.66e-03 | 126 |
GO:00163315 | Oral cavity | OSCC | morphogenesis of embryonic epithelium | 77/7305 | 147/18723 | 6.63e-04 | 3.72e-03 | 77 |
GO:004209816 | Oral cavity | OSCC | T cell proliferation | 100/7305 | 199/18723 | 7.93e-04 | 4.27e-03 | 100 |
GO:00060817 | Oral cavity | OSCC | cellular aldehyde metabolic process | 36/7305 | 60/18723 | 7.94e-04 | 4.27e-03 | 36 |
GO:004308710 | Oral cavity | OSCC | regulation of GTPase activity | 165/7305 | 348/18723 | 7.94e-04 | 4.27e-03 | 165 |
GO:00016558 | Oral cavity | OSCC | urogenital system development | 160/7305 | 338/18723 | 1.03e-03 | 5.31e-03 | 160 |
GO:00721758 | Oral cavity | OSCC | epithelial tube formation | 69/7305 | 132/18723 | 1.32e-03 | 6.56e-03 | 69 |
GO:003003819 | Oral cavity | OSCC | contractile actin filament bundle assembly | 57/7305 | 106/18723 | 1.42e-03 | 6.84e-03 | 57 |
GO:004314919 | Oral cavity | OSCC | stress fiber assembly | 57/7305 | 106/18723 | 1.42e-03 | 6.84e-03 | 57 |
GO:19016173 | Oral cavity | OSCC | organic hydroxy compound biosynthetic process | 115/7305 | 237/18723 | 1.73e-03 | 8.18e-03 | 115 |
GO:002261214 | Oral cavity | OSCC | gland morphogenesis | 62/7305 | 118/18723 | 1.91e-03 | 8.94e-03 | 62 |
GO:003223119 | Oral cavity | OSCC | regulation of actin filament bundle assembly | 56/7305 | 105/18723 | 1.99e-03 | 9.23e-03 | 56 |
GO:00330771 | Oral cavity | OSCC | T cell differentiation in thymus | 42/7305 | 75/18723 | 2.09e-03 | 9.63e-03 | 42 |
GO:006104116 | Oral cavity | OSCC | regulation of wound healing | 69/7305 | 134/18723 | 2.19e-03 | 9.95e-03 | 69 |
GO:00468906 | Oral cavity | OSCC | regulation of lipid biosynthetic process | 85/7305 | 171/18723 | 2.79e-03 | 1.21e-02 | 85 |
GO:00192167 | Oral cavity | OSCC | regulation of lipid metabolic process | 154/7305 | 331/18723 | 3.00e-03 | 1.30e-02 | 154 |
GO:00620128 | Oral cavity | OSCC | regulation of small molecule metabolic process | 155/7305 | 334/18723 | 3.30e-03 | 1.41e-02 | 155 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501028 | Oral cavity | OSCC | Alzheimer disease | 244/3704 | 384/8465 | 1.18e-15 | 3.60e-14 | 1.83e-14 | 244 |
hsa0502228 | Oral cavity | OSCC | Pathways of neurodegeneration - multiple diseases | 292/3704 | 476/8465 | 1.60e-15 | 4.47e-14 | 2.28e-14 | 292 |
hsa051659 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa0520526 | Oral cavity | OSCC | Proteoglycans in cancer | 128/3704 | 205/8465 | 4.00e-08 | 3.12e-07 | 1.59e-07 | 128 |
hsa0522516 | Oral cavity | OSCC | Hepatocellular carcinoma | 97/3704 | 168/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 97 |
hsa0491926 | Oral cavity | OSCC | Thyroid hormone signaling pathway | 73/3704 | 121/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 73 |
hsa041504 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
hsa0439016 | Oral cavity | OSCC | Hippo signaling pathway | 86/3704 | 157/8465 | 3.30e-03 | 8.24e-03 | 4.20e-03 | 86 |
hsa0436014 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
hsa05010112 | Oral cavity | OSCC | Alzheimer disease | 244/3704 | 384/8465 | 1.18e-15 | 3.60e-14 | 1.83e-14 | 244 |
hsa05022112 | Oral cavity | OSCC | Pathways of neurodegeneration - multiple diseases | 292/3704 | 476/8465 | 1.60e-15 | 4.47e-14 | 2.28e-14 | 292 |
hsa0516514 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa05205111 | Oral cavity | OSCC | Proteoglycans in cancer | 128/3704 | 205/8465 | 4.00e-08 | 3.12e-07 | 1.59e-07 | 128 |
hsa0522517 | Oral cavity | OSCC | Hepatocellular carcinoma | 97/3704 | 168/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 97 |
hsa04919112 | Oral cavity | OSCC | Thyroid hormone signaling pathway | 73/3704 | 121/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 73 |
hsa0415012 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
hsa0439017 | Oral cavity | OSCC | Hippo signaling pathway | 86/3704 | 157/8465 | 3.30e-03 | 8.24e-03 | 4.20e-03 | 86 |
hsa0436015 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
WNT4 | FZD5_LRP5 | WNT4_FZD5_LRP5 | WNT | CRC | AD |
WNT4 | FZD6_LRP5 | WNT4_FZD6_LRP5 | WNT | Endometrium | ADJ |
WNT4 | FZD4_LRP6 | WNT4_FZD4_LRP6 | WNT | Endometrium | ADJ |
WNT4 | FZD6_LRP6 | WNT4_FZD6_LRP6 | WNT | Endometrium | ADJ |
WNT4 | FZD4_LRP6 | WNT4_FZD4_LRP6 | WNT | Endometrium | AEH |
WNT4 | FZD4_LRP5 | WNT4_FZD4_LRP5 | WNT | HNSCC | OSCC |
WNT4 | FZD6_LRP5 | WNT4_FZD6_LRP5 | WNT | HNSCC | OSCC |
WNT4 | FZD6_LRP6 | WNT4_FZD6_LRP6 | WNT | HNSCC | OSCC |
WNT4 | FZD6_LRP5 | WNT4_FZD6_LRP5 | WNT | HNSCC | Precancer |
WNT4 | FZD6_LRP6 | WNT4_FZD6_LRP6 | WNT | HNSCC | Precancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WNT4 | SNV | Missense_Mutation | c.872C>T | p.Thr291Met | p.T291M | P56705 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-A1-A0SQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | ac | SD | |
WNT4 | SNV | Missense_Mutation | c.193G>A | p.Asp65Asn | p.D65N | P56705 | protein_coding | tolerated(0.14) | benign(0.065) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
WNT4 | SNV | Missense_Mutation | novel | c.646N>A | p.Glu216Lys | p.E216K | P56705 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-S3-AA11-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | CR |
WNT4 | insertion | Nonsense_Mutation | novel | c.183_184insTCTCTACTAAAAATACAAAAAAATTAGCCGGGCGTGGTGGC | p.Glu62SerfsTer9 | p.E62Sfs*9 | P56705 | protein_coding | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
WNT4 | SNV | Missense_Mutation | novel | c.374N>G | p.Thr125Arg | p.T125R | P56705 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
WNT4 | SNV | Missense_Mutation | rs121908652 | c.247N>T | p.Arg83Trp | p.R83W | P56705 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WNT4 | SNV | Missense_Mutation | c.536N>A | p.Ala179Asp | p.A179D | P56705 | protein_coding | tolerated(0.44) | benign(0.124) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
WNT4 | SNV | Missense_Mutation | rs760357534 | c.289N>A | p.Val97Ile | p.V97I | P56705 | protein_coding | tolerated(0.08) | benign(0.16) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
WNT4 | SNV | Missense_Mutation | c.125N>T | p.Thr42Met | p.T42M | P56705 | protein_coding | tolerated(0.31) | possibly_damaging(0.759) | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
WNT4 | SNV | Missense_Mutation | c.85N>A | p.Ala29Thr | p.A29T | P56705 | protein_coding | deleterious(0.01) | probably_damaging(0.923) | TCGA-DC-6155-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Ancillary | leucovorin | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |